Pluvicto Cost in India
Unlock Exclusive Discount : Your Gateway to Premium Healthcare with Medsurge India Health Value Card.
Unlock Exclusive Discount : Your Gateway to Premium Healthcare with Medsurge India Health Value Card.
PLUVICTO® (lutetium Lu 177 vipivotide tetraxetan) is approved to treat adult patients with PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) who have previously been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy.
Pluvicto Drug in India is a radioactive medication that is injected into a vein. As the drug enters the body, it binds to malignant cells and directs radioactive material to locations where the cancer has spread (metastases). The FDA has currently approved this medicine for the Treatment of Metastatic Castrate-Resistant Prostate Cancer.
Pluvicto is a radiopharmaceutical (a drug with a trace of radioactivity) that contains the active ingredient lutetium (177Lu) vipivotide tetraxetan.
Pluvicto is a medication used to treat prostate cancer (a gland in the male reproductive system). It is used when cancer has spread to other parts of the body, is progressive, castration-resistant (worsens despite treatment to lower levels of the male sex hormone testosterone), and the cancer cells have a protein on their surface called prostate-specific membrane antigen (PSMA) (PSMA-positive prostate cancer).
Pluvicto is used in combination with Androgen Deprivation Therapy in India (treatment to reduce male sex hormones) in people who have previously been treated with androgen receptor pathway inhibitors (prostate cancer drugs) and “Taxanes” (type cancer medicine). Pluvicto and androgen deprivation therapy may also include androgen receptor pathway inhibitors.
It is one of the types of precision Cancer Treatment in India that combines a targeted molecule (ligand) and a therapeutic radioisotope (a radioactive particle). Pluvicto binds to target cells when it enters into the bloodstream, including prostate cancer cells that produce PSMA, a transmembrane protein. Once attached, the radioisotope’s energy emissions damage the target cells and adjacent ones, interfering with their capacity to proliferate and/or inducing cell death.
Once you fulfill the following mentioned criteria, you’re referring doctor will recommend this treatment to manage your metastatic prostate cancer:
To undergo this treatment, you must have good bone marrow and kidney function, as well as overall mobility (able to perform self-care and not immobilized or in a wheelchair):
Affordable Pluvicto cost in India starts from INR 39,19,000 (47,000 USD). Also, Prostate Cancer Treatment cost in India start from 5000 USD. This cost in India is significantly lower when compared to the Cost of Prostate Cancer Treatment in the United States.
Additionally, there are a number of variables that affect the cost of medical treatment in India, this includes the type of treatment, the method employed, as well as the hospital and location of choice, the doctor’s qualifications, and so on. For this reason alone, many people come from all over the world for medical care in India for a variety of reasons, such as the Pluvicto cost in India being much lower compared to other countries which is by far the most important.
Know More About – Nuclear Medicine Therapy
This Targeted PSMA Treatment in India employs radiation to reduce prostate cancer cells. It contains medication that:
Before beginning treatment, you will have blood extracted and a PSMA-PET scan. The scan will reveal whether you have prostate cancer cells in your body. This scan, combined with your medical history and blood testing, will help your doctors determine whether Pluvicto is right for you.
Each treatment follows the same schedule. You will be:
Tiredness, dry mouth, nausea (feeling sick), anemia (low level of red blood cells), decreased appetite, and constipation are the most common Pluvicto side effects (which may affect more than one in ten people).
Anemia, thrombocytopenia (low levels of blood platelets), lymphopenia (low levels of lymphocytes, a kind of white blood cell), and fatigue are the most common significant side effects (which may occur up to one in every twenty persons).
Kidney toxicity (decreased kidney function) and myelosuppression (decreased bone marrow function) are the most serious potential side effects.
Outlook
Pluvicto's approval is a significant clinical achievement for individuals with advanced mCRPC, as it can considerably increase survival rates for those with few treatment options. Pluvicto is an important innovation in the field of precision medicine for prostate cancer.
Pluvicto is the first FDA-approved targeted radioligand therapy (RLT) that combines a targeting molecule (ligand) with a therapeutic radioisotope (a radioactive particle) for people eligible with mCRPC. Pluvicto is expected to be available to physicians and patients within the upcoming period of several weeks.
A: Pluvicto therapy is administered in six sequential infusions. The infusions are scheduled roughly 6 weeks apart. Each infusion will take place in MSK's main hospital. You will get regular blood tests to monitor your health while your Pluvicto treatment.
A: Bicalutamide, often known as Casodex, is a cancer treatment medication. It is a prostate cancer treatment.
A: You may be eligible if you have prostate cancer that has gone beyond the prostate and has progressed despite prior treatments (including hormonal therapies and at least one chemotherapy).
A: Although there is no cure for benign prostatic hyperplasia (BPH), generally known as an enlarged prostate, there are several effective treatment options. Treatments target prostate development, which causes BPH symptoms. Once prostate development begins, it frequently continues until medical therapy is initiated.
A: Novartis AG (Basel, Switzerland) markets PluvictoTM. PSMA-617 was created by the German Cancer Research Centre and the University Hospital Heidelberg in Heidelberg, Germany.
Nuclear Medicine
Consultant
29 years of experience
MIOT International, Chennai
View Doctor
Nuclear Medicine
Director
35 Years
Max Super Speciality Hospital, Saket, New Delhi
View Doctor
Nuclear Medicine
Consultant
25 Years
Max Superspeciality Hospital, Shalimar Bagh, New Delhi
View Doctor
Nuclear Medicine
DNB, MNAMS, FANMB
Fortis Memorial Research Institute, Gurgaon
View Doctor
Nuclear Medicine
MBBS, DNB, Senior Resident
9 years of experience
Fortis Memorial Research Institute, Gurgaon
View Doctor
Nuclear Medicine
MBBS, DNB, FEBNM, Fellow Theranostics
Fortis Memorial Research Institute, Gurgaon
View Doctor
Nuclear Medicine
Ph.D, M.Sc., Clinical Research Officer
Fortis Memorial Research Institute, Gurgaon
View Doctor
By using our site, you agree to our Terms and Conditions, Privacy Policy and Refund Policy. Medsurge India provides reliable healthcare information and treatment options to support informed decision-making. Our content is designed to support and complement the guidance of your treating doctor, helping you feel informed and confident throughout your healthcare journey. We also Accept International Payments.
Copyright © 2025 NSM ONLINE SOLUTIONS PRIVATE LIMITED. All rights reserved.
 (1).png)